CD22-targeting monoclonal antibody

This page covers all CD22-targeting monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD22.

Targets

CD22

Phase 2 pipeline (1)

• EVO301 · Evommune, Inc. · Immunology
  EVO301 is a monoclonal antibody targeting CD22.

Patent intelligence

• cd22 targeting monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates